Prostate cancer is the most common cancer among men and the risk increases with age. Lu-177-PSMA is a theranostic radiopharmaceutical which is used to treat metastatic prostate cancer. Using the PRRT (Peptide Receptor Radionuclide Therapy) technique, this radiopharmaceutical binds to metastatic prostate tumor cells quite intelligently and selectively, so it can destroy them thoroughly. Moreover, due to being a gamma emitter, Lu-177-PSMA can be used for imaging purposes and following up of the treatments.
Radiopharmaceutical
theragnostic